Accordion Bioreactor | An innovative high capacity Accordion bioreactor technology for high performance and low cost microalgae production

Summary
Access to vital raw ingredients for food/feed production is an increasing challenge in several industries. Biopharmia is a Norwegian company focusing on cultivation of microalgae through its development of a proprietary bioreactor. Through years of expertise and collaborations with experts in the field of microalgae growth, Biopharmia have developed and patented the Accordion bioreactor, a proven and efficient platform for industrial scale production of high quality microalgae, at lower energy and decreased production cost, compared to other solutions. This technology aims to strengthen Europe’s position in the microalgae market, which is currently weak due to cheaper, low quality foreign competitors. The technology describes the unique wave configuration comprising the frame work of the bioreactor, which contributes to higher productivity and lower cost of production and investment when compared to competing technologies. The modular design of this closed system greatly minimises the risk of contamination and can be easily adapted to large scale production. Biopharmia need to undertake the proposed innovation project to develop and further test the Accordion technology with multiple algae strains. The company has a close collaboration with the University of Arizona (UA) and has demonstrated the efficiency and productivity of its bioreactors through extensive testing at UA. Biopharmia has supplied biomass to a number of entities in Norway with very good results. Biopharmia has Letters of Intent about supply of biomass to two Norwegian customers in different segments, food supplements and aquaculture. In 2012 the company raised €1 million in private venture capital from IFE Venture. Biopharmia intends to establish initial production using the Accordion technology for the clients the company have an LOI with before expanding production.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/744603
Start date: 01-01-2017
End date: 30-04-2017
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

Access to vital raw ingredients for food/feed production is an increasing challenge in several industries. Biopharmia is a Norwegian company focusing on cultivation of microalgae through its development of a proprietary bioreactor. Through years of expertise and collaborations with experts in the field of microalgae growth, Biopharmia have developed and patented the Accordion bioreactor, a proven and efficient platform for industrial scale production of high quality microalgae, at lower energy and decreased production cost, compared to other solutions. This technology aims to strengthen Europe’s position in the microalgae market, which is currently weak due to cheaper, low quality foreign competitors. The technology describes the unique wave configuration comprising the frame work of the bioreactor, which contributes to higher productivity and lower cost of production and investment when compared to competing technologies. The modular design of this closed system greatly minimises the risk of contamination and can be easily adapted to large scale production. Biopharmia need to undertake the proposed innovation project to develop and further test the Accordion technology with multiple algae strains. The company has a close collaboration with the University of Arizona (UA) and has demonstrated the efficiency and productivity of its bioreactors through extensive testing at UA. Biopharmia has supplied biomass to a number of entities in Norway with very good results. Biopharmia has Letters of Intent about supply of biomass to two Norwegian customers in different segments, food supplements and aquaculture. In 2012 the company raised €1 million in private venture capital from IFE Venture. Biopharmia intends to establish initial production using the Accordion technology for the clients the company have an LOI with before expanding production.

Status

CLOSED

Call topic

SMEInst-08-2016-2017

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-1-2016-2017
SMEInst-08-2016-2017 Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth
H2020-SMEINST-2-2016-2017
SMEInst-08-2016-2017 Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.2. SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy
H2020-EU.3.2.3. Unlocking the potential of aquatic living resources
H2020-EU.3.2.3.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-08-2016-2017 Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth
H2020-SMEINST-2-2016-2017
SMEInst-08-2016-2017 Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth
H2020-EU.3.2.5. Cross-cutting marine and maritime research
H2020-EU.3.2.5.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-08-2016-2017 Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth
H2020-SMEINST-2-2016-2017
SMEInst-08-2016-2017 Supporting SMEs efforts for the development - deployment and market replication of innovative solutions for blue growth